Thorp HH. More questions than answers. Science. 2023;382:1213. https://doi.org/10.1126/science.adn3693.

Article  PubMed  Google Scholar 

Watanabe JH, Kwon J, Nan B, Reikes A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc. 2024;64:133–8. https://doi.org/10.1016/j.japh.2023.10.002.

Article  CAS  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N. Engl J Med. 2023;389:2221–32. https://doi.org/10.1056/NEJMoa2307563.

Article  CAS  PubMed  Google Scholar 

Pourabhari Langroudi A, Chen AL, Basran S, Sommer ER, Stinson J, Cheng Y-S, et al. Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data. Int J Impot Res 2025:1–7. https://doi.org/10.1038/s41443-025-01061-2.

Vestlund J, Jerlhag E. The glucagon-like peptide-1 receptor agonist, exendin-4, reduces sexual interaction behaviors in a brain site-specific manner in sexually naïve male mice. Horm Behav. 2020;124:104778. https://doi.org/10.1016/j.yhbeh.2020.104778.

Article  CAS  PubMed  Google Scholar 

Vestlund J, Jerlhag E. Glucagon-like peptide-1 receptors and sexual behaviors in male mice. Psychoneuroendocrinology. 2020;117:104687. https://doi.org/10.1016/j.psyneuen.2020.104687.

Article  CAS  PubMed  Google Scholar 

Able C, Liao B, Saffati G, Maremanda A, Applewhite J, Nasrallah AA, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Int J Impot Res 2024. https://doi.org/10.1038/s41443-024-00895-6.

Bajaj HS, Gerstein HC, Rao-Melacini P, Basile J, Colhoun H, Conget I, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol. 2021;9:484–90. https://doi.org/10.1016/S2213-8587(21)00115-7.

Article  CAS  PubMed  Google Scholar 

Lisco G, Bartolomeo N, De Tullio A, De Pergola G, Guastamacchia E, Jirillo E, et al. Long-acting glucagon-like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study. Andrology. 2024;12:633–42. https://doi.org/10.1111/andr.13519.

Article  CAS  PubMed  Google Scholar 

Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360–4. https://doi.org/10.1016/s0302-2838(03)00305-1.

Article  PubMed  Google Scholar 

Pozzi E, Capogrosso P, Boeri L, Belladelli F, Baudo A, Schifano N, et al. Longitudinal risk of developing cardiovascular diseases in patients with erectile dysfunction-which patients deserve more attention? J Sex Med. 2020;17:1489–94. https://doi.org/10.1016/j.jsxm.2020.03.012.

Article  CAS  PubMed  Google Scholar